Events

Wired Health w/ Joanna Shields

Join BenevolentAI’s CEO Joanna Shields at Wired Health where she will be speaking about forging new frontiers in drug discovery by uniting human and artificial intelligence.

While the past year has reinforced the fragility of human health, it has also demonstrated the value of leveraging AI to solve some of healthcare's greatest challenges. The speech will draw on BenevolentAI's pioneering work and powerful collaborations with leading pharma companies to further illustrate where AI has had a proven impact, both during the pandemic and in drug discovery more generally. Joanna will reflect on lessons learned from her leadership experience in big tech and government to lay out her vision for the future of scientific discovery: where human and artificial intelligence are united to solve complex pharmaceutical puzzles, unlock the value of vast data sets, and deliver new life-changing treatments to patients in need.


Register here →


Joanna Shields

Chief Executive Officer

Joanna is a tech industry veteran with over 25 years experience building and scaling global companies including Facebook, Bebo, Aol, Google, Real Networks and Efi. Prior to joining Benevolent AI, she served in UK Government as Under Secretary of State and Minister for Internet Safety & Security, Digital Economy Adviser and Chair and CEO of TechCityUK. Joanna is passionate about creating responsible technology that benefits humanity. She is a leading advocate for children's rights and safety online and founder of the WeProtect Global Alliance, and a Life Peer of the House of Lords.

More Posts

You Might Also Like

News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
Notifications of persons discharging managerial responsabilities
May 5, 2022
News
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
News
PDMR Notification (Jean Raby)
May 5, 2022
News
Notifications of Major Holdings
Apr 29, 2022